Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

The receptor tyrosine kinase‑like orphan receptor (ROR1) is aberrantly expressed on chronic lymphocytic leukemia (CLL) cells and promotes survival signaling through NF‑κB, ERK1/2, and mTORC1. Zilovertamab is a humanized monoclonal antibody targeting ROR1. We conducted a multicenter phase 1b/2 study of zilovertamab plus...

M. Choi, E. Ghia, T. Siddiqi et al. · 0 citations
Open access Sep 2026

From Daffodils to Drug Leads: Amaryllidaceae Alkaloids Target Protein Translation in Chronic Lymphocytic Leukemia to Induce Selective Apoptosis

Targeting protein translation is a promising strategy in oncology, especially for malignancies dependent on short-lived survival factors. The clinical translation inhibitor homoharringtonine (HHT) was recently discontinued in the U.S. due to poor solubility and cardiotoxicity, creating an urgent need for new leads. W...

Rong Chen, Ryan J. Rutledge, C. King et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.